Publications

PUBLICATIONS

By clicking on the link in the journal name, you are directed to the manuscript.

Natural Killer cells

  1. Beelen NA, Valckx VTC, Bos GMJ, Rensen SS, Wieten L. Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy. Best Prac Res Clin Haematol. 2024 Sep;37(3):101568.
  2. Gong Y, Germeraad WTV, Zhang X, Wu N, Li B, Janssen L, He Z, Gijbels MJJ, Wu B, Gijsbers BLMG, Olieslagers TI, Bos GMJ, Zheng L, Klein Wolterink RGJ. NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody.  Mol Ther. 2024 Jun 27:S1525-0016(24)00424-6.
  3. Beelen NA, Molenbroeck SJJ, Groeneveld L, Voorter CE, Bos GMJ, Wieten L. HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma.  Immunogenetics. 2024 Jun;76(3):155-164.
  4. Beelen NA, Aberle MR, Bruno V, Olde Damink SWM, Bos GMJ, Rensen SS, Wieten L. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids. Front Immunol. 2023 Jul 14;14:1133796.
  5. Ehlers FAI, Mahaweni NM, van de Waterweg Berends A, Saya T, Bos GMJ, Wieten L. Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages. Cancer Immunol Immunother. 2023 Jun;72(6):1789-1801.
  6. Beelen NA, Ehlers FAI, Kooreman LFS, Bos GMJ, Wieten L. An in vitro model to monitor natural killer cell effector functions against breast cancer cells derived from human tumor tissue. Methods Cell Biol. 2023;173:133-153.
  7. Beelen NA, Ehlers FAI, Bos GMJ, Wieten L. Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell‑mediated antibody‑dependent cellular cytotoxicity in cancer immunotherapy. Cancer Immunol Immunother. 2023 Apr;72(4):797-804.
  8. Ehlers FAI, Beelen NA, van Gelder M, Evers TMJ, Smidt ML, Kooreman LFS, Bos GMJ, Wieten L. ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response. Cancers. June 2021; 13, 3232.
  9. Gong Y, Klein Wolterink RGJ, Gulaia V, Cloosen S, Ehlers FAI, Wieten L, Graus YF, Bos GMJ, Germeraad WTV. Defucosylation of tumor-specific humanized anti-MUC1 monoclonal antibody enhances NK cell-mediated anti-tumor cell Cytotoxicity. Cancers, May 2021, 13, 2579.
  10. Ehlers FAI, Mahaweni NM, Olieslagers TI, Bos GMJ, Wieten L. Activated natural killer cells withstand the relatively low glucose concentrations found in the bone marrow of multiple myeloma patients. Front Oncol. May 2021, 622896.
  11. Gong Y, Klein Wolterink RJG, Wang JX, Bos GMJ, Germeraad WTV. Generation chimeric antigen receptor Natural Killer cells for tumor immunotherapy. J Hematol Oncol. 2021. 14:73.
  12. Van Elssen C, van Gorkom G, Voorter C, von dem Borne P, Meijer E, Wieten L, Bos G. Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors. Ann Hematol. 2021 Jan;100(1):181-187.
  13. Gong Y, Klein Wolterink RGJ, Janssen I, Groot AJ, Bos GMJ, Germeraad WTV. Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor. Mol Ther Methods Clin Dev. 2020 Jun 12; 17: 634–646.
  14. Mahaweni NM, Ehlers FAI, Bos GMJ, Wieten L. Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A. Front Immunol. 2018 Dec 4;9:2848.
  15. Mahaweni NM, Ehlers FAI, Sarkar S, Janssen JWH, Tilanus MGJ, Bos GMJ, Wieten L. NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment. Front Immunol. 2018 Jun 22;9:1415.
  16. Mahaweni NM, Bos GMJ, Mitsiades CS, Tilanus MGJ, Wieten L. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions. Cancer Immunol Immunother. 2018 Jun;67(6):861-872.
  17. van Gelder M, Vanclée A, van Elssen CHMJ, Hupperets P, Wieten L, Bos GMJ. Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer. Breast Cancer Res Treat. 2017 Feb;161(3):421-433.
  18. Sarkar S, Noort W, Van Elssen CHMJ, Groen R, van Bloois L, van Gelder M, Schouten HC, Tilanus MGJ, Germeraad WTV, Wieten L, Martens ACM, Bos GMJ. Alloreactive natural killer cells have anti‐tumor capacity against disseminated human multiple myeloma in Rag2-/-γC-/-mice when combined with low dose cyclophosphamide and total body irradiation. J Mol Cytotherapy 2015 Sept; 1: 001.
  19. Sarkar S, van Gelder M, Noort W, Xu Y, Rouschop KM, Groen R, Schouten HC, Tilanus MGJ, Germeraad WTV, Martens ACM, Bos GMJ, Wieten L. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. Cancer Immunol Immunother. 2015 Aug;64(8):951-63.
  20. Huijskens MJAJ, Walczak M, Sarkar S, Atrafi F, Senden-Gijsbers BLMG, Bos GMJ, Wieten L, Germeraad WTV. Ascorbic acid promotes proliferation of NK cell populations in culture systems applicable for NK cell therapy. Cytotherapy. 2015 May;17(5):613-20.
  21. Wieten L, Mahaweni NM, Voorter CE, Bos GMJ, Tilanus MGJ. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens. 2014 Dec;84(6):523-35.
  22. Sarkar S, Germeraad WTV, Rouschop KM, Steeghs EM, van Gelder M, Bos GMJ, Wieten L. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One. 2013 May 28;8(5):e64835.
  23. Frings PW, Van Elssen CH, Wieten L, Matos C, Hupperets PS, Schouten HC, Bos GMJ, van Gelder M. Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice. Breast Cancer Res Treat. 2011 Dec;130(3):773-81.
  24. Vanclée A, van Gelder M, Schouten HC, Bos GMJ. Graft-versus-tumor effects on murine mammary carcinoma in a model of nonmyeloablative haploidentical stem cell transplantation. Bone Marrow Transplant. 2006 Jun;37(11):1043-9.
  25. Vanclée A, Lutgens LC, Oving EB, Deutz NE, Gijbels MJ, Schouten HC, Bos GMJ.Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant. 2005 Nov;36(10):907-15.